Adjuvant immunotherapy in neonatal sepsis: advances in treatment / 国际儿科学杂志

ABSTRACT

Systemic infections in newborns cause significant morbidity and mortality in spite of appropriate antimicrobial therapy. Consequently, Immune and adjuvant therapy has emerged as a potential adjuvant therapeutic modality to reduce the morbidity and mortality associated with neonatal sepsis. There were many recent trails including a few of animal trails described the use of intravenous immunoglobulin and colony stimulating factors in neonatal sepsis. In addition, the most recent findings describing the use of probiotics, glutamine supplementation, recombinant human protein C, lactoferrin and pentoxifylline in the treatment of neonatal sepsis have been reviewed.